Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (521-530 of 688) with videos related to

Pageof 69
Sort By:
Circulation|March 15, 2006
The Seattle Heart Failure Model: prediction of survival in heart failureWayne C Levy, Dariush Mozaffarian, David T Linker, et al.
International Journal of Cardiology|December 1, 2012
Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANTSally C Inglis, Judith Bebchuk, Sultan A Al-Suhaim, et al.
Journal of the American College of Cardiology|October 19, 2004
Task force 2: Investigator participation in clinical researchRobert M Califf, Steven E Nissen, Anthony N DeMaria, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 17, 2023
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup AnalysisPantelis Sarafidis, Rajiv Agarwal, Bertram Pitt, et al.
International Journal of Cardiology|February 4, 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Kidney Medicine|December 4, 2023
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD TrialsJohn M Flack, Rajiv Agarwal, Stefan D Anker, et al.
Journal of the American College of Cardiology|December 3, 2014
Noncardiac comorbidities in heart failure with reduced versus preserved ejection fractionRobert J Mentz, Jacob P Kelly, Thomas G von Lueder, et al.
JAMA Cardiology|August 25, 2018
Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|November 30, 2019
Influence of Age on Efficacy and Safety of Spironolactone in Heart FailureOrly Vardeny, Brian Claggett, Muthiah Vaduganathan, et al.
Archives of Internal Medicine|January 14, 2004
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysesCharles H Hennekens, Frank M Sacks, Andrew Tonkin, et al.
Pageof 69

Showing results (521-530 of 688) with videos related to

Sort By:
Pageof 69
Circulation|March 15, 2006
The Seattle Heart Failure Model: prediction of survival in heart failureWayne C Levy, Dariush Mozaffarian, David T Linker, et al.
International Journal of Cardiology|December 1, 2012
Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANTSally C Inglis, Judith Bebchuk, Sultan A Al-Suhaim, et al.
Journal of the American College of Cardiology|October 19, 2004
Task force 2: Investigator participation in clinical researchRobert M Califf, Steven E Nissen, Anthony N DeMaria, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 17, 2023
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup AnalysisPantelis Sarafidis, Rajiv Agarwal, Bertram Pitt, et al.
International Journal of Cardiology|February 4, 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Kidney Medicine|December 4, 2023
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD TrialsJohn M Flack, Rajiv Agarwal, Stefan D Anker, et al.
Journal of the American College of Cardiology|December 3, 2014
Noncardiac comorbidities in heart failure with reduced versus preserved ejection fractionRobert J Mentz, Jacob P Kelly, Thomas G von Lueder, et al.
JAMA Cardiology|August 25, 2018
Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|November 30, 2019
Influence of Age on Efficacy and Safety of Spironolactone in Heart FailureOrly Vardeny, Brian Claggett, Muthiah Vaduganathan, et al.
Archives of Internal Medicine|January 14, 2004
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysesCharles H Hennekens, Frank M Sacks, Andrew Tonkin, et al.
Pageof 69